武汉华康世纪洁净科技股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 一、年度募集资金存放与使用情况鉴证报告 1-2 二、武汉华康世纪洁净科技股份有限公司关于 2024 年度募集资金 存放与使用情况的专项报告 3-18 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 目 录 | | | 中汇会鉴[2025]5161号 武汉华康世纪洁净 ...

武汉华康世纪洁净科技股份有限公司 2024 年度审计报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 目 录 | | 页 次 | | --- | --- | | 一、审计报告 | 1-6 | | 二、财务报表 | 7-18 | | (一) 合并资产负债表 | 7-8 | | (二) 合并利润表 | 9 | | (三) 合并现金流量表 | 10 | | (四) 合并所有者权益变动表 | 11-12 | | (五) 母公司资产负债表 | 13-14 | | (六) 母公司利润表 | 15 | | (七) 母公司现金流量表 | 16 | | (八) 母公司所有者权益变动表 | 17-18 | 三、财务报表附注 19-133 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、1 ...

国联民生证券承销保荐有限公司 关于武汉华康世纪洁净科技股份有限公司 2024年度内部控制评价报告 的核查意见 内部控制是由企业董事会、监事会、经理层和全体员工实施的、旨在实现控制 目标的过程。在公司治理层的监督下，按照企业内部控制规范体系的规定，设计、 实施和维护有效的内部控制，评价其有效性，并如实披露内部控制评价报告是公司 董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织领 导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保 证本报告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实 性、准确性和完整性承担个别及连带责任。 建立与实施内部控制的目标是合理保证企业经营管理合法合规、资产安全、财 务报告及相关信息真实完整，提高经营效率和效果，促进企业实现发展战略。由于 内部控制存在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情 况的变化可能导致内部控制变得不恰当，或对控制政策或程序遵循的程度降低，根 据内部控制评价结果推测未来内部控制的有效性具有一定的风险。 二、内部控制评价工作组织情况 内部控制评价工作由公司董事会及其下设的审计委员会领导 ...

武汉华康世纪洁净科技股份有限公司 董事会对独立董事独立性评估的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等要求，武汉华康世纪洁净科技股份有限公司（以下简称"公司"）董事会就公 司在任独立董事余亮、齐亮、郭孟焕的独立性情况进行评估并出具如下专项意见： 经核查独立董事余亮、齐亮、郭孟焕的任职经历以及签署的相关自查文件， 公司董事会认为上述人员未在公司担任除独立董事以外的任何职务，也未在公司 主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可 能妨碍其进行独立客观判断的关系，不存在其他影响独立董事独立性的情况。因 此，公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》中对独立董事独立性的相 关要求。 武汉华康世纪洁净科技股份有限公司 董事会 2025 年 4 月 25 日 ...

武汉华康世纪洁净科技股份有限公司 独立董事述职报告 武汉华康世纪洁净科技股份有限公司 2024年度独立董事述职报告 各位股东及股东代理人： 本人作为武汉华康世纪洁净科技股份有限公司(以下简称"公司")的独立 董事、第二届董事会薪酬与考核委员会召集人、第二届董事会审计委员会委员、 第二届董事会提名委员会委员及第二届董事会战略委员会委员，严格按照《中 华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》 （以下简称"《证券法》"）《上市公司独立董事管理办法》《武汉华康世纪 洁净科技股份有限公司章程》（以下简称"《公司章程》"）等相关法律法规 和规章制度的规定和要求，在2024年的工作中，忠实勤勉、恪尽职守，积极出席 各次董事会和股东大会，认真审议董事会各项议案，对公司相关事项发表了独立、 客观、专业的意见，切实维护了公司和股东尤其是中小股东的利益。现将2024年 度任职期间本人履行独立董事职责的情况向各位股东及股东代理人汇报如下： 一、独立董事的基本情况 本人郭孟焕，1981年3月出生，中国国籍，无境外永久居留权。2006年6月 至2008年8月，在吉实富（上海）投资咨询有限公司，任分析师；20 ...

武汉华康世纪洁净科技股份有限公司 独立董事述职报告 武汉华康世纪洁净科技股份有限公司 2024年度独立董事述职报告 各位股东及股东代理人： 本人作为武汉华康世纪洁净科技股份有限公司(以下简称"公司")的独立 董事、第二届董事会审计委员会召集人、第二届董事会薪酬与考核委员会委员， 严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和 国证券法》（以下简称"《证券法》"）《上市公司独立董事管理办法》《武汉 华康世纪洁净科技股份有限公司章程》（以下简称"《公司章程》"）等相关 法律法规和规章制度的规定和要求，在2024年的工作中，忠实勤勉、恪尽职守， 积极出席各次董事会和股东大会，认真审议董事会各项议案，对公司相关事项发 表了独立、客观、专业的意见，切实维护了公司和股东尤其是中小股东的利益。 现将2024年度任职期间本人履行独立董事职责的情况向各位股东及股东代理人汇 报如下： 一、独立董事的基本情况 本人余亮，1976年12月出生，中国国籍，无境外永久居留权。2000年6月至 2001年7月，在武汉正浩会计师事务所，任项目经理；2001年8月至2004年7月，在 湖北中信会计师事务有限责任公司， ...

武汉华康世纪洁净科技股份有限公司 独立董事述职报告 武汉华康世纪洁净科技股份有限公司 2024年度独立董事述职报告 各位股东及股东代理人： 本人作为武汉华康世纪洁净科技股份有限公司(以下简称"公司")的独立 董事、第二届董事会提名委员会召集人、第二届董事会审计委员会委员，严格按照 《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券 法》（以下简称"《证券法》"）《上市公司独立董事管理办法》《武汉华康世 纪洁净科技股份有限公司章程》（以下简称"《公司章程》"）等相关法律法 规和规章制度的规定和要求，在2024年的工作中，忠实勤勉、恪尽职守，积极出 席各次董事会和股东大会，认真审议董事会各项议案，对公司相关事项发表了独 立、客观、专业的意见，切实维护了公司和股东尤其是中小股东的利益。现将 2024年度任职期间本人履行独立董事职责的情况向各位股东及股东代理人汇报如 下： 一、独立董事的基本情况 本人齐亮，1973年2月出生，中国国籍，无境外永久居留权。1997年至2021年， 在武汉乾坤律师事务所，担任律师；2001年至2018年，在湖北中和信律师事务所， 担任律师；2018年至2024年12月 ...

Financial Performance - The company's revenue for Q1 2025 was ¥295,271,024.99, representing a 28.54% increase compared to ¥229,705,391.58 in the same period last year[5]. - The net loss attributable to shareholders decreased by 9.72% to ¥-28,954,967.04 from ¥-32,071,670.93 year-on-year[5]. - The net profit excluding non-recurring items improved by 10.20%, amounting to ¥-29,990,803.71 compared to ¥-33,396,511.35 in the previous year[5]. - Basic and diluted earnings per share increased by 10.00% to ¥-0.27 from ¥-0.30 year-on-year[5]. - Net profit for the current period was -¥28,035,877.68, an improvement from -¥32,071,670.93 in the previous period, indicating a reduction in losses[20]. - Basic and diluted earnings per share were both -¥0.27, compared to -¥0.30 in the previous period[21]. Cash Flow and Assets - Cash flow from operating activities showed a decline of 28.30%, totaling ¥-192,510,065.52 compared to ¥-150,043,637.68 in the same period last year[5]. - Cash flow from operating activities showed a net outflow of -¥192,510,065.52, worsening from -¥150,043,637.68 in the previous period[22]. - Cash flow from investing activities resulted in a net outflow of -¥20,495,165.43, compared to -¥61,453,823.42 in the previous period, indicating reduced investment losses[23]. - Cash flow from financing activities recorded a net outflow of -¥2,081,893.05, a significant decrease from a net inflow of ¥165,475,678.21 in the previous period[23]. - The ending cash and cash equivalents balance was ¥730,221,634.91, up from ¥126,526,729.46 in the previous period[23]. - The company's cash and cash equivalents decreased from approximately 1.05 billion RMB to about 821.24 million RMB, reflecting a decline of around 21.6%[15][17]. - As of March 31, 2025, the company's total assets amounted to approximately 3.96 billion RMB, a decrease from 4.23 billion RMB at the beginning of the period[15][17]. - Total assets decreased by 6.37% to ¥3,957,324,709.16 from ¥4,226,342,757.17 at the end of the previous year[5]. Shareholder Equity and Liabilities - Shareholder equity attributable to the parent company decreased by 2.28% to ¥1,757,654,235.78 from ¥1,798,630,395.33 at the end of the previous year[5]. - Total current liabilities decreased from approximately 1.49 billion RMB to about 1.23 billion RMB, a decline of around 17.8%[16][17]. - The company's total equity decreased from approximately 1.80 billion RMB to about 1.78 billion RMB, a reduction of about 0.8%[17]. Orders and Operational Efficiency - The company reported an increase in orders due to the growth of sales and technical support personnel, indicating a positive trend in order backlog and new orders[8]. - The company is implementing comprehensive budgeting, process reforms, and personnel qualification assessments to enhance efficiency and reduce costs[8]. Research and Development - Research and development expenses increased to ¥21,405,242.23, up from ¥16,462,194.83 in the previous period, reflecting a focus on innovation[19]. Convertible Bonds - The company issued 7.5 million convertible bonds with a total value of 750 million RMB, set to be traded on the Shenzhen Stock Exchange starting January 9, 2025[12][13]. - The company plans to prioritize the issuance of convertible bonds to existing shareholders before offering any remaining bonds to the public[12].

Financial Performance - The company's operating revenue for 2024 was approximately ¥1.71 billion, representing a 6.64% increase compared to ¥1.60 billion in 2023[16]. - The net profit attributable to shareholders decreased by 37.75% to approximately ¥66.81 million in 2024, down from ¥107.33 million in 2023[16]. - The net profit after deducting non-recurring gains and losses was approximately ¥57.68 million, a decrease of 36.51% from ¥90.84 million in the previous year[16]. - Basic earnings per share decreased by 38.24% to ¥0.63 in 2024, down from ¥1.02 in 2023[16]. - Total assets increased by 46.22% to approximately ¥4.23 billion at the end of 2024, compared to ¥2.89 billion at the end of 2023[16]. - The net assets attributable to shareholders increased by 2.55% to approximately ¥1.80 billion at the end of 2024, compared to ¥1.75 billion at the end of 2023[16]. - The company achieved operating revenue of 1,707.83 million yuan, a year-on-year increase of 6.64%[46]. - The net profit attributable to shareholders decreased by 37.75% to 66.81 million yuan, while the net profit after deducting non-recurring gains and losses fell by 36.51% to 57.68 million yuan[46]. - The company has a backlog of orders amounting to 2.753 billion yuan, with 2.07 billion yuan from medical specialty orders and 393 million yuan from laboratory orders[46]. Cash Flow and Financial Management - The net cash flow from operating activities improved significantly to approximately ¥147.56 million, compared to a negative cash flow of ¥187.36 million in 2023, marking a 178.76% increase[16]. - The company has a net cash flow from operating activities of 147.56 million yuan, a significant increase of 178.76%[46]. - Operating cash inflow increased by 15.77% to ¥1,717,885,727.63 in 2024, while operating cash outflow decreased by 6.04% to ¥1,570,323,385.39, resulting in a net cash flow from operating activities of ¥147,562,342.24, a significant improvement of 178.76%[116]. - Net cash flow from financing activities rose by 105.05% to ¥763,050,861.29, primarily due to funds raised from issuing convertible bonds[117]. - The company's cash and cash equivalents increased significantly by 1,872.44% to ¥77,276,020, driven by the issuance of convertible bonds[117]. Market and Industry Trends - The domestic cleanroom market is projected to exceed $500 billion by 2032, with a compound annual growth rate (CAGR) of over 7% from 2023 to 2032[32]. - The cleanroom industry is experiencing a shift towards high-end development, driven by the increasing complexity and demand for cleanroom technology[29]. - The global nuclear medicine market is projected to reach $23 billion by 2028, with a 18.7% annual growth in China's nuclear medicine diagnosis volume[109]. Research and Development - The company has filed for 23 invention patents and 17 utility model patents, successfully obtaining 8 invention patents and 9 utility model patents during the year[50]. - The company has filed 64 new patent applications in the current period, with 36 granted, bringing the total to 329 applications and 253 granted patents[90]. - R&D investment amounted to ¥64,496,790 in 2024, a decrease of 24.36% from ¥85,227,776.77 in 2023, with the ratio of R&D investment to operating revenue falling from 5.32% to 3.78%[114]. Strategic Initiatives - The company is focusing on optimizing medical purification system solutions to enhance service efficiency and resource utilization in healthcare institutions[35]. - The company has established an electronic cleanroom division to focus on semiconductor and high-tech industry cleanroom solutions[48]. - The company has established an innovation development research institute to focus on key core technology breakthroughs and address industry challenges[84]. - The company aims to enhance service efficiency by over 40% through digitalization of service processes and preventive maintenance systems[109]. - The company is transitioning towards smart operation service providers, leveraging technology to enhance customer engagement and market competitiveness[109]. Governance and Management - The company has established a comprehensive internal control system to manage risks and ensure normal operations[176]. - The board of directors operates independently, with specialized committees providing professional advice to enhance decision-making efficiency[171]. - The company maintains a clear separation from its controlling shareholder in terms of assets, personnel, and operations, ensuring independent business capabilities[170]. - The company has a strong governance structure with independent board members and management, ensuring no interference from controlling shareholders in personnel decisions[182]. Risks and Challenges - The company faces a significant risk of large accounts receivable and potential bad debt losses due to long payment cycles associated with its medical purification system integration business, with receivables typically taking about 2 years to collect[157]. - The cash flow risk is heightened by the capital-intensive nature of the purification system integration business, which requires substantial upfront funding, leading to potential negative cash flow if clients delay payments[159]. - The company is at risk of declining gross margins due to increased market competition and rising costs, prompting a focus on refined management and product innovation to enhance competitiveness[161].